Characterization of specific miRNAs in acute monocytic leukemia
LIU Jinli1, LIU Shuge2, XIONG Qian2, HAN Li3, LI Wei1, WANG Wanheng3, ZHANG Zhaojun1,2,4, LI Quanzhen1
1.School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, 325035; 2.CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, 100101; 3.Guoxinkaier Biotechnology of Shanxi, Taiyuan, 030006; 4.University of Chinese Academy of Sciences, Beijing, 100049
LIU Jinli,LIU Shuge,XIONG Qian, et al. Characterization of specific miRNAs in acute monocytic leukemia[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(10): 703-708,715.
Abstract:Objective: To characterize the molecular markers of microRNA (miRNA) with specifically high expression in acute monocytic leukemia. Methods: A batch of miRNAs was firstly screened out for their significantly higher expression in THP-1 (acute monocytic leukemia cell line) by analyzing high-throughput miRNA transcriptome sequencing data of THP-1 and K562 (chronic myeloid leukemia cell line). These miRNAs were further tested in the THP-1 and K562 cell line by quantitative real-time PCR (qRT-PCR) to obtain the specifically high expressed miRNAs in THP-1 cell line. Finally, these screened miNRAs were verified in bone marrow samples of acute monocytic leukemia patients by qRT-PCR. The finally verified miRNAs could serve the candidates for clinical diagnosis of this disease in the future. Results: Three miRNAs that are specifically highly expressed in acute monocytic leukemia including let-7d-5p, miR-221-3p and miR-222-3p were characteried. Conclusion: By integrating the bioinformatics analysis and verification in cell lines and patient bone marrow samples, we finally characterized 3 miRNAs as potential molecular diagnostic markers in acute monocytic leukemia.
[1] ESTEY E, D HNER H. Acute myeloid leukaemia[J]. Lancet, 2006, 368(9550): 1894-1907.
[2] LOWENBERG B, DOWNING J R, BURNETT A. Acute myeloid leukemia[J]. N Engl J Med, 1999, 341(14): 1051-1062.
[3] MI S, LU J, SUN M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia[J]. Proc Natl Acad Sci U S A, 2007, 104(50): 19971-19976.
[4] BARTEL D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[5] CHENG A M, BYROM M W, SHELTON J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis[J]. Nucleic Acids Res, 2005, 33(4): 1290-1297.
[6] CALIN G A, CROCE C M. MicroRNA signatures in human cancers[J]. Nat Rev Cancer, 2006, 6(11): 857-866.
[7] ESQUELA-KERSCHER A, SLACK F J. Oncomirs-microRNAs with a role in cancer[J]. Nat Rev Cancer, 2006, 6(4): 259-269.
[8] MARTON S, GARCIA M, ROBELLO C, et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis[J]. Leukemia, 2008, 22(2): 330-338.
[9] TAKADA S, YAMASHITA Y, BEREZIKOV E, et al. MicroRNA expression profiles of human leukemias[J]. Leukemia, 2008, 22(6): 1274-1278.
[10] KUCHENBAUER F, MORIN R D, ARGIROPOULOS B, et al. In-depth characterization of the microRNA transcriptome in a leukemia progression model[J]. Genome Res, 2008, 18(11): 1787-1797.
[11] XIONG Q, YANG Y, WANG H, et al. Characterization of miRNomes in acute and chronic myeloid leukemia cell lines [J]. Genomics Proteomics Bioinformatics, 2014, 12(2): 79-91.
[12] WANG H, HU H, ZHANG Q, et al. Dynamic transcriptomes of human myeloid leukemia cells[J]. Genomics, 2013, 102(4): 250-256.
[13] LEE R C, FEINBAUM R L, AMBROS V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843-854.
[14] CALIN G A, CROCE C M. MicroRNA-cancer connection:the beginning of a new tale[J]. Cancer Res, 2006, 66(15): 7390-7394.
[15] CALIN G A, SEVIGNANI C, DUMITRU C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J]. Proc Natl Acad Sci U S A, 2004, 101(9): 2999-3004.
[16] FABBRI M, GARZON R, ANDREEFF M, et al. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications[J]. Leukemia, 2008, 22(6): 1095-1105.
[17] GARZON R, CROCE C M. MicroRNAs in normal and malignant hematopoiesis[J]. Curr Opin Hematol, 2008, 15(4): 352-358.
[18] VASILATOU D, PAPAGEORGIOU S, PAPPA V, et al. The role of microRNAs in normal and malignant hematopoiesis [J]. Eur J Haematol, 2010, 84(1): 1-16.
[19] YENDAMURI S, CALIN G. The role of microRNA in human leukemia: a review[J]. Leukemia, 2009, 23(7): 1257-1263.
[20] CALIN G A, DUMITRU C D, SHIMIZU M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia[J]. Proc Natl Acad Sci U S A, 2002, 99(24): 15524-15529.
[21] FAYYAD-KAZAN H, BITAR N, NAJAR M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia[J]. J Transl Med, 2013, 11(31): 1-10.
[22] MARCUCCI G, RADMACHER M D, MAHARRY K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia[J]. N Engl J Med, 2008, 358(18): 1919-1928.
[23] ZHU Y D, WANG L, SUN C, et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia[J]. Med Oncol, 2012, 29(4): 2323-2331.
[24] ZHI F, CAO X, XIE X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia[J]. PLoS One, 2013, 8(2): e56718.
[25] MARCUCCI G, MAHARRY K S, METZELER K H, et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients[J]. J Clin Oncol, 2013, 31(17):2086-2093.
[26] CAMMARATA G, AUGUGLIARO L, SALEMI D, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia[J]. Am J Hematol, 2010, 85(5): 331-339.
[27] VEERLA S, LINDGREN D, KVIST A, et al. MiRNA expression in urothelial carcinomas: Important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31[J]. Int J Cancer, 2009, 124(9): 2236-2242.
[28] GALARDI S, MERCATELLI N, GIORDA E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1[J]. J Biol Chem, 2007, 282(32): 23716-23724.
[29] LE SAGE C, NAGEL R, EGAN D A, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation[J]. EMBO J, 2007, 26(15): 3699-3708.
[30] MERCATELLI N, COPPOLA V, BONCI D, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice[J].PLoS One, 2008, 3(12): e4029.
[31] ZHANG C, KANG C, YOU Y, et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo[J]. Int J Oncol, 2009, 34(6): 1653-1660.
[32] PARK J K, KOGURE T, NUOVO G J, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J]. Cancer Res, 2011, 71(24): 7608-7616.
[33] TAKAMIZAWA J, KONISHI H, YANAGISAWA K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival [J]. Cancer Res, 2004, 64(11): 3753-3756.
[34] PARK S M, SHELL S, RADJABI A R, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2[J]. Cell Cycle, 2007, 6(21): 2585-2590.
[35] SHELL S, PARK S M, RADJABI A R, et al. Let-7 expression defines two differentiation stages of cancer[J]. Proc Natl Acad Sci USA, 2007, 104(27): 11400-11405.
[36] BRUECKNER B, STRESEMANN C, KUNER R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function[J]. Cancer Res, 2007, 67(4): 1419-1423.
[37] LAWRIE C H, CHI J, TAYLOR S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma[J]. J Cell Mol Med, 2009, 13(7): 1248-1260.